Research programme: pain therapeutics - TransMolecular
Latest Information Update: 27 Nov 2007
At a glance
- Originator TransMolecular
- Class
- Mechanism of Action Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 11 Jul 2003 Transmolecular is seeking partners to develop new chemical entries for the treatment of pain in the US (http://www.transmolecular.com)
- 11 Jul 2003 Early research in Pain in USA (unspecified route)